Back to CYTR Stock Lookup

CYTR – Press Releases

Apr 15, 2014 04:15 PM Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors of the May 13, 2014 Deadline to File for Lead Plaintiff in the Securities Fraud Class Action Against CytRx Corporation -- CYTR
Apr 10, 2014 07:00 AM CytRx Announces Research and Development Day and Webcast
Apr 4, 2014 12:40 PM Technical Update on Active Stocks -- Research on CytRx, FireEye, Yandex, and Hewlett-Packard
Apr 3, 2014 07:00 AM CytRx to Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results at the 2014 AACR Annual Meeting
Mar 31, 2014 07:00 AM CytRx Receives Orphan Medicinal Product Designation from the European Commission for Aldoxorubicin in Soft Tissue Sarcoma
Mar 27, 2014 07:00 AM CytRx Issues Statement Regarding Recent Lawsuits
Mar 24, 2014 07:00 AM CytRx Initiates Pivotal Global Phase 3 Clinical Trial with Aldoxorubicin for Second-Line Treatment of Soft Tissue Sarcoma
Mar 21, 2014 08:52 PM /C O R R E C T I O N -- Robbins Arroyo LLP/
Mar 21, 2014 08:52 PM Attention CytRx Corporation Investors: CytRx Misled Investors According to a Recently Filed Class Action
Mar 21, 2014 07:30 PM Gainey McKenna & Egleston Reminds Investors That a Class Action Lawsuit Has Been Filed Against CytRx Corporation -- CYTR
Mar 21, 2014 09:00 AM Lieff Cabraser Announces Class Action Litigation Against CytRx Corporation - CYTR
Mar 18, 2014 07:00 PM Gainey McKenna & Egleston Announces a Class Action Lawsuit has Been Filed Against CytRx Corporation -- CYTR
Mar 18, 2014 04:01 PM Lifshitz & Miller Law Firm Announces Investigation of CytRx Corporation, DURECT Corporation, Hastings Entertainment, Inc., Immunomedics, Inc. and NII Holdings, Inc.
Mar 18, 2014 03:01 PM Investor Alert: Holzer & Holzer Announces Class Action Filed on Behalf of Investors in CytRx Corporation
Mar 18, 2014 09:01 AM Zeldes Haeggquist & Eck, LLP Announces Investigation of CytRx Corporation
Mar 17, 2014 07:00 AM CytRx Establishes Research and Development Team and Opens New Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform
Mar 5, 2014 06:00 AM CytRx Reports 2013 Financial Results
Feb 13, 2014 09:00 AM Catasys Announces Transition to a New Board of Directors
Feb 5, 2014 12:00 PM CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Feb 3, 2014 06:30 AM CytRx to Present at the 16th Annual BIO CEO & Investor Conference on February 10, 2014, in New York City
Jan 31, 2014 09:00 AM CytRx Announces Pricing of Approximately $75 Million Public Offering of Common Stock
Jan 30, 2014 04:01 PM CytRx Announces Proposed Public Offering of Common Stock
Jan 23, 2014 06:30 AM CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi’s Sarcoma
Jan 21, 2014 06:30 AM CytRx Receives FDA Approval to Extend Aldoxorubicin Dosing Cycles until Disease Progression in Upcoming Pivotal, Global Phase 3 Trial for Soft Tissue Sarcomas

Back to CYTR Stock Lookup